Table 3. ERα and PR association with disease recurrence.
Variables | All patients | Patients with pT1a disease | ||||||
---|---|---|---|---|---|---|---|---|
N | (%) | 5-yr CIR | P | N | (%) | 5-yr CIR | P | |
ERα nucleus | 0.38 | 0.018 | ||||||
Negative | 756 | (83) | 17% | 336 | (81) | 8% | ||
Positive | 157 | (17) | 21% | 81 | (19) | 20% | ||
ERα cytoplasm | 0.37 | 0.14 | ||||||
Negative | 827 | (91) | 18% | 380 | (91) | 11% | ||
Positive | 86 | (9) | 14% | 37 | (9) | 5% | ||
PR nucleus | 0.18 | 0.96 | ||||||
Negative | 791 | (87) | 17% | 347 | (83) | 10% | ||
Positive | 119 | (13) | 23% | 69 | (17) | 12% | ||
PR cytoplasm | 0.42 | 0.65 | ||||||
Negative | 794 | (87) | 18% | 348 | (84) | 10% | ||
Positive | 116 | (13) | 16% | 68 | (16) | 10% |
Significant P-values (<0.05) are shown in bold.
ER, estrogen receptor; PR, progesterone receptor; CIR, cumulative incidence of recurrence